West German Study Group
WSG - Women's Cancer Study Group GmbH is a German academic clinical research organization founded in 1994, conducting biomarker-guided breast cancer clinical trials across more than 200 breast centers with over 15,000 enrolled patients. It specializes in therapy de-escalation through the ADAPT umbrella trial program integrating genomic signatures and early tumor response assessment.
- Company typePrivate
- Founded1994
- HeadquartersMönchengladbach, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What West German Study Group does
West German Study Group (WSG), legally WSG - Women's Cancer Study Group GmbH, is an academic research organization founded in 1994 in Düsseldorf by Prof. Ulrike Nitz and operating from Mönchengladbach, Germany. WSG specializes in the design, organization, and execution of investigator-initiated clinical trials for breast cancer treatment optimization, with a focus on biomarker-guided therapy de-escalation. Its core platform is the ADAPT (Adjuvant Dynamic marker-Adjusted Personalized Therapy) umbrella trial program, a modular clinical trial architecture that integrates early tumor response assessment (Ki-67 endocrine response testing) with genomic risk profiling (Oncotype DX Recurrence Score, MammaPrint) to enable personalized treatment decisions across multiple breast cancer subtypes. WSG collaborates with over 200 breast centers across all German federal states and has enrolled more than 15,000 patients in studies including ADAPTcycle, ADAPT-HER2-IV, ADAPT-TN-III, ADAPTlate, Keyriched-1, PROOFS-Registry, and PlanB. The organization maintains a tumor bank of more than 10,000 patient samples at Medical University Hannover and conducts translational research services (TRAFO) and local therapy research (LT).
WSG's business model is that of an academic clinical research organization funded through public research grants (notably the German Research Foundation/DFG), pharmaceutical industry collaborations for investigator-initiated trials, and academic institutional partnerships. It does not sell commercial products or services; rather, it generates revenue by conducting and managing multicenter clinical studies whose findings influence national and international breast cancer treatment guidelines. Leadership comprises internationally renowned breast cancer experts, including Prof. Nadia Harbeck (ESMO Lifetime Achievement Award 2020, candidate for ESMO President 2027-2028), Prof. Peter Schmid (Barts Cancer Institute), Prof. Ulrike Nitz, Prof. Oleg Gluz, Prof. Sherko Kümmel, and Prof. Monika Graeser. Recent strategic activity includes international expansion through ADAPTlate into additional European countries, new hires from top CROs in 2024, and AI-driven biomarker research (multimodal histopathology models, multiomic predictive analytics) presented at ASCO 2024. Awards include the German Cancer Prize 2023 and the Employer of the Future award 2023.
West German Study Group firmographics
Firmographics- Name
- West German Study Group
- Legal name
- WSG - Women´s Cancer Study Group GmbH
- Website
- https://wsg-online.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WSG - Women's Cancer Study Group GmbH is a German academic clinical research organization founded in 1994, conducting biomarker-guided breast cancer clinical trials across more than 200 breast centers with over 15,000 enrolled patients. It specializes in therapy de-escalation through the ADAPT umbrella trial program integrating genomic signatures and early tumor response assessment.
- Ownership category
- akta.pro rank
West German Study Group industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Breast Oncology (HLAKAFAJ)
- akta.pro secondary industries
- Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where West German Study Group is headquartered
LocationHeadquarters
- HQ city
- Mönchengladbach
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
West German Study Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Funding: Academic research organization funded through grants, public research funding (DFG), and potentially pharmaceutical industry collaborations for investigator-initiated trials.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
West German Study Group product offering
Product offeringCore offering
WSG is an academic research organization that designs, organizes, and conducts biomarker-guided clinical trials for breast cancer therapy optimization, centered on the ADAPT umbrella trial program. It integrates genomic signatures (Oncotype DX, MammaPrint) with early tumor response assessment (Ki-67) to identify patients who can safely avoid chemotherapy and personalize neoadjuvant and adjuvant treatment across HR+/HER2-, HER2+, and triple-negative subtypes. The organization operates through a network of over 200 collaborating breast centers across Germany and supports translational biomarker research and local therapy (surgery, radiotherapy, imaging) investigations.
Product overview
WSG (Women´s Cancer Study Group) is an academic research institution specializing in clinical trials for breast cancer treatment optimization. The core offering is the ADAPT umbrella study program with multiple parallel substudies (ADAPTcycle, ADAPT-HER2-IV, ADAPT-TN-III, ADAPTlate, Keyriched-1) targeting different breast cancer subtypes (HR+/HER2-, HER2+, triple-negative). Studies integrate genomic biomarkers (Oncotype DX, MammaPrint) and early tumor response assessment to enable personalized therapy de-escalation. Supporting services include translational research (TRAFO) for biomarker discovery and local therapy research. The portfolio spans neoadjuvant, adjuvant, and registry studies with over 15,000 patients enrolled across Germany.
Differentiator
Problem solved
Functional benefit
Products and services
- ADAPT Study Program
- ADAPTcycle
- ADAPT-HER2-IV
- ADAPT-TN-III
- PROOFS-Registry
- Keyriched-1
- ADAPTlate
- PlanB Study
- Translational Research (TRAFO) Services
- Local Therapy Research (LT) Services
Quantifiable outcome
- Nearly half of patients initially considered for chemotherapy could safely avoid it using ADAPT approach with Ki-67 response testing and Recurrence Score
- +3 more outcomes
Companies that use West German Study Group
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles3 records
West German Study Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability4 records
Feature4 records
West German Study Group partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and supporting.
- Breast International Group (BIG)coreWSG is a longstanding member organization of BIG, the worldwide network of breast cancer study groups. WSG featured in BIG's 'Research in Focus' journal highlighting ADAPT HR+/HER2- study results.
- Medical University Hannover - Institute of PathologycoreProf. Hans Kreipe leads the WSG tumor bank at MHH, containing tumor samples from over 10,000 patients from WSG studies.
- Queen Mary University LondonmajorWSG serves as national coordinator for ECLIPSE and BARBICAN studies in Germany, collaborating with Queen Mary University in London on international breast cancer research.
- Heinrich-Heine-Universität DüsseldorfcoreWSG was founded at Heinrich-Heine-Universität Düsseldorf in 1994. Ongoing collaboration in translational research.
- University of ColognesupportingCollaboration in translational research alongside other academic partners.
- Netherlands Cancer Institute - Antoni van Leeuwenhoek HospitalsupportingInternational collaboration in translational breast cancer research.
- EORTC (European Organisation for Research and Treatment of Cancer)majorWSG served as German national coordinator for MINDACT study, contributing over 800 patients in Germany through associated centers.
- German Cancer Research Center (DKFZ) HeidelbergcoreCollaboration in DFG-funded project on molecular determinants of primary endocrine resistance in luminal breast cancer using ADAPT study tumor samples.
Scale indicators9 records
Recent moves8 records
Expansion highlights5 records
West German Study Group competitors and assessment
Company assessmentBroad incumbents
- Parexel International: Large global CRO with extensive oncology clinical operations. Comparable in breast cancer trial execution capability but operates as a commercial incumbent across many indications rather than as an academic specialist.
Direct peers
- EORTC: EORTC is the pan-European academic clinical cancer research organization running multi-center trials across solid tumors. WSG already collaborates with EORTC (MINDACT national coordinator in Germany) and is structurally comparable as an academic sponsor.
- UNICANCER: UNICANCER is the French federation of academic cancer centers running breast cancer group trials (e.g., CANTO cohort). Comparable as a national academic oncology research organization with similar IIT model.
- SOLTI Breast Cancer Research Group: SOLTI is a Spanish academic group dedicated to breast cancer clinical and translational research, running biomarker-driven trials. Comparable to WSG in mission, scale, and pharma-sponsored IIT model.
- Breast International Group (BIG): BIG is the worldwide network of academic breast cancer trial groups; WSG is itself a BIG member. BIG coordinates large international trials (e.g., MINDACT, APHINITY) and is structurally the meta-organization WSG participates in.
- NSABP Foundation: NSABP is a long-established US academic breast and bowel cancer trial group whose adjuvant trials have shaped global guidelines. Direct international peer for guideline-influencing adjuvant breast cancer research.
- I-SPY Consortium: I-SPY runs adaptive neoadjuvant breast cancer trials using biomarker-guided platform designs. Closely comparable to WSG's ADAPT umbrella trial architecture for adaptive, biomarker-driven de-escalation.
- Translational Research in Oncology (TRIO): TRIO is a global academic-led oncology research organization running biomarker-driven breast cancer trials. Comparable in mission, international footprint, and pharma-sponsored IIT orientation.
- German Breast Group (GBG): GBG is a leading German academic breast cancer study group running large Phase II/III trials (e.g., GeparNuevo, GeparTrio). It is the closest direct competitor in Germany for academic breast cancer trials and pharma IIT funding.
- Austrian Breast & Colorectal Cancer Study Group (ABCSG): ABCSG is an Austrian academic cooperative group running large adjuvant breast cancer trials (e.g., ABCSG P-series). Direct peer in the DACH region with similar academic IIT and adjuvant trial focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
West German Study Group social profiles
Digital presenceWest German Study Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
West German Study Group leadership team
Management profileNumber of profiles
Profiles16 records
West German Study Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
West German Study Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about West German Study Group
What does West German Study Group do?
WSG is an academic research organization that designs, organizes, and conducts biomarker-guided clinical trials for breast cancer therapy optimization, centered on the ADAPT umbrella trial program. It integrates genomic signatures (Oncotype DX, MammaPrint) with early tumor response assessment (Ki-67) to identify patients who can safely avoid chemotherapy and personalize neoadjuvant and adjuvant treatment across HR+/HER2-, HER2+, and triple-negative subtypes. The organization operates through a network of over 200 collaborating breast centers across Germany and supports translational biomarker research and local therapy (surgery, radiotherapy, imaging) investigations.
Is West German Study Group a public or private company?
West German Study Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was West German Study Group founded?
West German Study Group was founded in 1994. It employs 11 to 50 people.
Where is West German Study Group based?
West German Study Group is headquartered in Mönchengladbach, Germany, in the Europe region.
How does West German Study Group make money?
One revenue line is on record: clinical Trial Funding.
Who are West German Study Group's main competitors?
Parexel International is listed as a broad incumbent. Direct peers are EORTC, UNICANCER, SOLTI Breast Cancer Research Group, Breast International Group (BIG), NSABP Foundation, I-SPY Consortium, Translational Research in Oncology (TRIO), German Breast Group (GBG) and Austrian Breast & Colorectal Cancer Study Group (ABCSG).
Does West German Study Group have an API?
No public API is recorded for West German Study Group.
What industry is West German Study Group in?
West German Study Group's product category is Clinical Research Services. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAGAOAA, Clinical Operations & Monitoring FSP (CRA/CTM/Start-up). Its NAICS code is 541714 and its SIC code is 8731.